Multiple sclerosis and related disorders · 2025
Rituximab regimens and lymphocyte counts in patients with neuromyelitis optica: A systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ortiz-Salas Paola Andrea, Quilaguy-Jimenez Maria Alejandra, Castañeda Juan Sebastian, Gómez-Salazar Natalia, Pineda-Mateus Eliana
Аннотация
OBJECTIVE: To evaluate the utility of peripheral blood B-cell counts, specifically CD19+ and CD27+ lymphocytes by flow cytometry, in patients with neuromyelitis optica (NMO) treated with rituximab.
METHODS: A systematic review was conducted following the PRISMA guidelines. Searches were performed in PubMed, LILACS, Cochrane, and ClinicalTrials databases up to July 2024, including studies in English, Spanish, and French. Studies were selected based on predefined eligibility criteria, and data extraction was performed independently by two reviewer teams. Risk of bias was assessed using the JBI Critical Appraisal Tool, and the certainty of evidence was evaluated with the GRADE methodology.
RESULTS: A total of 3325 studies were identified, of which 22 met the inclusion criteria, analyzing 633 patients. Most studies used rituximab induction schemes of 375 mg/m² weekly (46%) or 1 g biweekly (38%). Retreatment protocols varied widely, and 84.6% of studies measured CD19+ cells, while 42.3 % also included CD27+ memory B cells. The most common depletion thresholds were <1% for CD19+ and <0.05% for CD27+. Repopulation occurred between 2.5 and 12.72 months, with 26% peaking at 6 months. Recurrent disease was reported in 200 patients (31.5%), with 64.5% of relapses associated with B-cell repopulation. However, 35% of relapses occurred without B-cell return. The quality of evidence was limited due to methodological heterogeneity, small sample sizes, and variability in monitoring protocols. CONCLUSIóN: B-cell repopulation appears to be temporally associated with relapses in NMO, highlighting the potential value of CD19+ and CD27+ monitoring by flow cytometry to guide retreatment strategies. However, relapses also occurred in the absence of repopulation, suggesting other pathophysiological mechanisms. There is a pressing need for standardized treatment protocols and prospective, multicenter studies to define the optimal use of B-cell monitoring in clinical practice.
METHODS: A systematic review was conducted following the PRISMA guidelines. Searches were performed in PubMed, LILACS, Cochrane, and ClinicalTrials databases up to July 2024, including studies in English, Spanish, and French. Studies were selected based on predefined eligibility criteria, and data extraction was performed independently by two reviewer teams. Risk of bias was assessed using the JBI Critical Appraisal Tool, and the certainty of evidence was evaluated with the GRADE methodology.
RESULTS: A total of 3325 studies were identified, of which 22 met the inclusion criteria, analyzing 633 patients. Most studies used rituximab induction schemes of 375 mg/m² weekly (46%) or 1 g biweekly (38%). Retreatment protocols varied widely, and 84.6% of studies measured CD19+ cells, while 42.3 % also included CD27+ memory B cells. The most common depletion thresholds were <1% for CD19+ and <0.05% for CD27+. Repopulation occurred between 2.5 and 12.72 months, with 26% peaking at 6 months. Recurrent disease was reported in 200 patients (31.5%), with 64.5% of relapses associated with B-cell repopulation. However, 35% of relapses occurred without B-cell return. The quality of evidence was limited due to methodological heterogeneity, small sample sizes, and variability in monitoring protocols. CONCLUSIóN: B-cell repopulation appears to be temporally associated with relapses in NMO, highlighting the potential value of CD19+ and CD27+ monitoring by flow cytometry to guide retreatment strategies. However, relapses also occurred in the absence of repopulation, suggesting other pathophysiological mechanisms. There is a pressing need for standardized treatment protocols and prospective, multicenter studies to define the optimal use of B-cell monitoring in clinical practice.